MannKind Corp. (MNKD)

[mick]

MannKind Corporation, a biopharmaceutical company, focuses on the
http://finviz.com/quote.ashx?t=mnkd

discovery, development, and commercialization of therapeutic products for diabetes patients in the United States. Its approved product is AFREZZA, a rapid-acting, inhaled insulin used to control high blood sugar in adults with type 1 and type 2 diabetes. MannKind Corporation has license and collaboration agreement with Sanofi-Aventis Deutschland GmbH for the development of AFREZZA. The company was founded in 1991 and is headquartered in Valencia, California.

Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Castagna Michael Chief Commercial Officer Aug 24 Buy 0.87 15,000 13,050 195,000 Aug 24 06:43 PM
Castagna Michael Chief Commercial Officer Aug 23 Buy 0.94 25,000 23,468 180,000 Aug 24 08:41 AM
PFEFFER MATTHEW J CEO, CFO, Director Aug 15 Buy 0.99 25,000 24,650 397,996 Aug 16 07:54 AM
Castagna Michael Chief Commercial Officer Aug 12 Buy 1.00 25,000 24,888 75,000 Aug 16 07:56 AM
Alinaya Rosabel Realica SVP, Prin Acctg Officer Jul 06 Sale 1.06 6,294 6,672 131,413 Jul 18 06:30 PM
Castagna Michael Chief Commercial Officer May 17 Buy 0.93 50,000 46,500 50,000 May 18 08:00 AM